SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, despite the efficacy of SMO inhibitors alone or in combination with TKIs in preclinical settings, efforts to implement these strategies for CML patient treatment have largely been hindered due to toxicity associated with SMO inhibition [76].